Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 43
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
World J Surg ; 43(2): 504-512, 2019 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-30229381

RESUMEN

BACKGROUND: Based on our long-term observation of medullary thyroid carcinoma (MTC) patients, we hypothesized that some MTCs have spontaneous deceleration or regression of tumor growth over a long term and that a minority may acquire growth acceleration. We thus compared the calcitonin doubling time (Ct-DT) in the earlier and later half-periods of MTC patients' postoperative course. METHODS: We followed 26 MTC patients (14 hereditary and 12 sporadic MTCs) with postoperative hypercalcitoninemia with periodic measurements of serum calcitonin (Ct) for >10 years without major interventions. The median period of Ct measurements was 18.3 years (range 10.6-30.2 years). We divided the individual patients' study periods into the earlier and later halves and calculated the Ct-DTs for both periods. RESULTS: In the hereditary group, the Ct-DT in the later half-period (Later-Ct-DT) was significantly longer than that in the earlier half-period (Earlier-Ct-DT) (median 20.0 years vs. 7.1 years, p = 0.013). These values in the sporadic group were 20.0 years versus 11.1 years, respectively (p =0.774). Twelve patients (seven hereditary and five sporadic) had Later-Ct-DTs significantly longer than their Earlier-Ct-DTs (median 27.4 years vs. 4.9 years) and good prognoses. Two patients (one hereditary, one sporadic) had Later-Ct-DTs significantly shorter than their Earlier-Ct-DTs, and both developed structural recurrence and died of the disease. CONCLUSION: Many of the hereditary and some of the sporadic MTC patients had elongated Ct-DTs over a long period, suggesting spontaneous deceleration and regression of tumor growth. A minority of the MTC patients showed Ct-DT shortening, suggesting tumor growth acceleration.


Asunto(s)
Calcitonina/sangre , Carcinoma Neuroendocrino/patología , Neoplasias de la Tiroides/patología , Adolescente , Adulto , Anciano , Carcinoma Neuroendocrino/sangre , Carcinoma Neuroendocrino/cirugía , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neoplasias de la Tiroides/sangre , Neoplasias de la Tiroides/cirugía , Factores de Tiempo , Adulto Joven
2.
Endocr J ; 66(2): 127-134, 2019 Feb 28.
Artículo en Inglés | MEDLINE | ID: mdl-30626761

RESUMEN

The revised Japan Association of Endocrine Surgeons (JAES)/Japanese Society of Thyroid Surgery (JSTS) guidelines for patients with papillary thyroid carcinoma (PTC) describe four risk classes: very-low-risk, low-risk, intermediate-risk, and high-risk. Here we conducted a retrospective analysis to evaluate the appropriateness of these guidelines' risk classification of PTCs. Lymph node recurrence-free, distant recurrence-free and cause-specific survivals at 15-year of high-risk group were significantly poorer than those at 15-year of intermediate-group and these survivals of intermediate-group were poorer than of low- or very-low-risk patients. In the subset analyses based on patient age (≥55 years and <55 years), we obtained the same results in both subsets. Age significantly worsen the whole prognosis of high-risk patients and cause-specific survival of intermediate-risk patients, but not the prognosis of low- or very-low-risk patients. Therefore, the risk classification of the revised JAES/JSTS guidelines is appropriate, and therapeutic strategies should be decided based on the risk class together with the patients' age.


Asunto(s)
Recurrencia Local de Neoplasia/patología , Cáncer Papilar Tiroideo/patología , Glándula Tiroides/patología , Neoplasias de la Tiroides/patología , Adolescente , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Niño , Femenino , Humanos , Japón , Metástasis Linfática/patología , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia/mortalidad , Guías de Práctica Clínica como Asunto , Pronóstico , Estudios Retrospectivos , Medición de Riesgo , Factores de Riesgo , Tasa de Supervivencia , Cáncer Papilar Tiroideo/mortalidad , Neoplasias de la Tiroides/mortalidad , Adulto Joven
3.
Endocr J ; 65(6): 621-627, 2018 Jun 27.
Artículo en Inglés | MEDLINE | ID: mdl-29618671

RESUMEN

Follicular thyroid carcinoma (FTC), a form of differentiated thyroid carcinoma, is the second most common malignancy arising from thyroid follicular cells. Recently, the tumor-node-metastasis (TNM) classification for differentiated thyroid carcinoma was revised from the 7th to the 8th edition. The diagnostic criteria for poorly differentiated carcinoma (PDC) were also updated in the latest World Health Organization (WHO) classification. In this study, we investigated whether these changes are appropriate for accurately predicting prognosis. Three hundred and twenty-nine patients diagnosed with postoperative pathologically confirmed FTC, who underwent initial surgery at our hospital between 1984 and 2004, were enrolled. For this study, patients were re-evaluated and diagnosed with FTC (N = 285) or PDC (N = 44) without typical nuclear findings of papillary thyroid carcinoma. For FTC, the 8th TNM classification was a more accurate predictor of prognosis than the 7th TNM classification. In the 8th TNM classification, cause-specific survival became significantly poorer from Stage I to IVB. The cause-specific survival of PDC based on the latest WHO classification was worse than, but did not significantly differ from, that of PDC based only on the former WHO classification. For PDC, neither of the TNM classifications could accurately predict prognosis. Taken together, we conclude that (1) the 8th TNM classification more accurately reflects the prognosis of FTC than the 7th TNM classification; (2) PDC based on the former WHO classification should be retained, at least in Japan; and (3) the TNM classification may not be suitable for predicting the prognosis of PDC.


Asunto(s)
Adenocarcinoma Folicular/patología , Ganglios Linfáticos/patología , Metástasis Linfática/patología , Neoplasias de la Tiroides/patología , Adenocarcinoma Folicular/mortalidad , Adulto , Anciano , Femenino , Humanos , Japón , Masculino , Persona de Mediana Edad , Pronóstico , Tasa de Supervivencia , Neoplasias de la Tiroides/mortalidad
4.
Endocr J ; 65(7): 707-716, 2018 Jul 28.
Artículo en Inglés | MEDLINE | ID: mdl-29681581

RESUMEN

The tumor-node-metastasis (TNM) staging system is most commonly adopted to evaluate the prognosis of patients with thyroid carcinoma. The 8th edition of the TNM staging system, an extensively revised version of the 7th edition, was recently released. We aimed to investigate whether and how well the 8th edition reflects the cause-specific survival (CSS) of patients with papillary thyroid carcinoma by analyzing the cases in 5,892 patients who underwent initial surgery at Kuma Hospital between 1987 and 2005. The median postoperative follow-up duration was 178 months (range: 6-357 months). One patient with T4b disease was excluded from the analysis. Overall, 116 (2.0%) patients died of thyroid carcinoma. The proportion of variance explained (PVE) for CSS in the 7th and 8th editions was 10.69 and 10.97, respectively. Using the 7th edition, CSS of patients with stage IVA and stage III disease was similar (p = 0.32). In contrast, using the 8th edition, CSS was poorer in stage II than in stage I (p < 0.001), in stage III than in stage II (p < 0.001), and in stage IVB than in stage III (p < 0.001). Similar results were observed for disease-free survival. Although we could not establish any objective evidence that the 8th edition is superior to the 7th edition, the 8th edition is simpler and more convenient, as it includes fewer stages and addresses the issue of the 7th edition where stage IVA and III patients had similar prognoses.


Asunto(s)
Carcinoma Papilar/patología , Metástasis Linfática/patología , Neoplasias de la Tiroides/patología , Adulto , Anciano , Carcinoma Papilar/mortalidad , Carcinoma Papilar/cirugía , Supervivencia sin Enfermedad , Femenino , Estudios de Seguimiento , Humanos , Japón , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Pronóstico , Tasa de Supervivencia , Neoplasias de la Tiroides/mortalidad , Neoplasias de la Tiroides/cirugía
5.
Endocr J ; 64(1): 59-64, 2017 Jan 30.
Artículo en Inglés | MEDLINE | ID: mdl-27667647

RESUMEN

The incidence of thyroid cancer is increasing rapidly in many countries, resulting in rising societal costs of the care of thyroid cancer. We reported that the active surveillance of low-risk papillary microcarcinoma had less unfavorable events than immediate surgery, while the oncological outcomes of these managements were similarly excellent. Here we calculated the medical costs of these two managements. We created a model of the flow of these managements, based on our previous study. The flow and costs include the step of diagnosis, surgery, prescription of medicine, recurrence, salvage surgery for recurrence, and care for 10 years after the diagnosis. The costs were calculated according to the typical clinical practices at Kuma Hospital performed under the Japanese Health Care Insurance System. If conversion surgeries were not considered, the 'simple cost' of active surveillance for 10 years was 167,780 yen/patient. If there were no recurrences, the 'simple cost' of immediate surgery was calculated as 794,770 yen/patient to 1,086,070 yen/patient, depending on the type of surgery and postoperative medication. The 'simple cost' of surgery was 4.7 to 6.5 times the 'simple cost' of surveillance. When conversion surgeries and recurrence were considered, the 'total cost' of active surveillance for 10 years became 225,695 yen/patient. When recurrence were considered, the 'total cost' of immediate surgery was 928,094 yen/patient, which was 4.1 times the 'total cost' of the active surveillance. At Kuma Hospital in Japan, the 10-year total cost of immediate surgery was 4.1 times expensive than active surveillance.


Asunto(s)
Carcinoma Papilar/terapia , Costos de la Atención en Salud , Neoplasias de la Tiroides/terapia , Tiroidectomía/economía , Espera Vigilante/economía , Carcinoma Papilar/economía , Carcinoma Papilar/patología , Humanos , Japón , Modelos Económicos , Recurrencia Local de Neoplasia/economía , Recurrencia Local de Neoplasia/cirugía , Terapia Recuperativa/economía , Neoplasias de la Tiroides/economía , Neoplasias de la Tiroides/patología , Tiroidectomía/métodos , Carga Tumoral , Espera Vigilante/métodos
6.
World J Surg ; 40(3): 523-8, 2016 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-26243564

RESUMEN

INTRODUCTION: Low-risk thyroid papillary microcarcinomas (PMCs) without evidence of metastasis grow slowly if at all. However, we recommended surgery for tumors touching the trachea (TR) or located in the course of the recurrent laryngeal nerve (RN). Here we compared the cases of low-risk PMC patients who underwent immediate surgery to cases of TR- and RN-involved PMCs. MATERIALS AND METHODS: We enrolled 1143 low-risk PMC patients who underwent immediate surgery in the years 2006-2014. The PMCs of 437 patients touched the TR on imaging studies: 270, 104, and 63 were graded as low, intermediate, and high risk, respectively, for TR invasion based on the angles between the tumor and the TR surface. The tumor was in the course of the RN in 144 patients, with 35 graded low risk and 109 high risk for RN invasion based on the normal rim of the thyroid in the direction of the RN. RESULTS: Invasion of the TR cartilage was observed only in high-risk patients. Peritracheal connective tissue was resected in 21, 15, and 6 of the high-, intermediate- and low-risk patients, respectively. Significant invasion of the RN requiring complete resection was observed in only nine patients at high risk for RN invasion. The incidence of TR invasion in high- and intermediate patients and the incidence of RN invasion in the high-risk patients were significantly higher than those of the low-risk patients. Tumors <7 mm did not show TR or RN invasion. CONCLUSION: Among PMCs that touched the TR or were located in the course of the RN, observation could be the first choice for tumors < 7 mm and those ≥ 7 mm judged as low risk for TR or RN invasion. However, for PMCs with high-risk features, immediate surgery after cytological diagnosis by a needle aspiration biopsy is recommended.


Asunto(s)
Carcinoma Papilar/cirugía , Recurrencia Local de Neoplasia/cirugía , Neoplasias de la Tiroides/cirugía , Tiroidectomía/métodos , Adulto , Anciano , Biopsia con Aguja Fina , Carcinoma Papilar/diagnóstico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Invasividad Neoplásica , Recurrencia Local de Neoplasia/diagnóstico , Pronóstico , Reoperación , Factores de Riesgo , Neoplasias de la Tiroides/diagnóstico , Tomografía Computarizada por Rayos X
7.
Endocr J ; 63(4): 323-8, 2016 Apr 25.
Artículo en Inglés | MEDLINE | ID: mdl-26632168

RESUMEN

Over 20 years ago, two Japanese institutions initiated an active surveillance policy for papillary microcarcinomas (PMCs) without high-risk features (such as clinical lymph node and distant metastases) and suspected trachea or recurrent laryngeal nerve invasion. Since the most recent American Thyroid Association (ATA) guidelines adopt active surveillance as a therapy option for low-risk PMCs, the number of institutions worldwide carrying out this policy can be expected to increase. However, before adopting an active surveillance strategy, some important clinical questions must be considered. In this review, conceivable clinical questions with our answers based on the present accumulation of low-risk PMC surveillance data are presented.


Asunto(s)
Carcinoma Papilar/terapia , Monitoreo Fisiológico/métodos , Neoplasias de la Tiroides/terapia , Espera Vigilante/métodos , Carcinoma Papilar/epidemiología , Carcinoma Papilar/patología , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Incidencia , Monitoreo Fisiológico/historia , Pronóstico , Factores de Riesgo , Tasa de Supervivencia , Neoplasias de la Tiroides/epidemiología , Neoplasias de la Tiroides/patología , Espera Vigilante/historia
8.
J Vet Med Sci ; 86(4): 363-367, 2024 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-38383002

RESUMEN

Ezetimibe is a cholesterol absorption inhibitor that blocks the intestinal absorption of both biliary and dietary cholesterol, thereby lowering primarily low density lipoprotein-cholesterol (LDL-chol) in human studies. This study aimed to investigate the effects of ezetimibe on dyslipidemia control in nine dogs with hypercholesterolemia. Changes in total cholesterol (T-chol) and each lipoprotein fractions were evaluated at 0, 2, and 4 months following initiation of ezetimibe treatment. A significant decrease in T-chol was observed, and a mean T-chol concentration below 400 mg/dL was achieved at 2 and 4 months. Furthermore, a significant decrease in LDL-chol was observed (-53.3% and -64.3% at 2 and 4 months, respectively). Taken together, treatment of ezetimibe could lower LDL-chol levels in dogs with hypercholesterolemia.


Asunto(s)
Anticolesterolemiantes , Azetidinas , Enfermedades de los Perros , Hipercolesterolemia , Perros , Humanos , Animales , Ezetimiba/uso terapéutico , LDL-Colesterol , Hipercolesterolemia/tratamiento farmacológico , Hipercolesterolemia/veterinaria , Azetidinas/uso terapéutico , Anticolesterolemiantes/uso terapéutico , Enfermedades de los Perros/tratamiento farmacológico
9.
J Comp Pathol ; 201: 100-104, 2023 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-36758478

RESUMEN

A 12-year-old castrated male Beagle dog presented with a 1-month history of progressive loss of appetite and cough. One month after the initial visit, a detailed clinical examination was performed due to weight loss and persistent cough. Computed tomography demonstrated diffuse opacification of the entire right lung and cranial lobe of the left lung. Samples of the pulmonary lesions obtained by fine-needle aspiration (FNA) were highly cellular with scattered and clustered foci of large round cells, suggestive of a round cell tumour. Ten days after the FNA, the dog was euthanized due to decreased activity and severe respiratory symptoms. At necropsy, enlargement of the entire right lung and cranial lobe of the left lung was seen. The external and cut surfaces of the lungs were homogeneously grey-white. Histopathological examination of sections of the right lung and the cranial lobe of the left lung revealed proliferation of large round or polygonal neoplastic cells arranged in nests of variable size separated by a thin fibrous stroma. Neoplastic cells were immunopositive for cytokeratin and thyroid transcription factor-1 but negative for vimentin, CD204, chromogranin A and synaptophysin. On the basis of these findings, the tumour was diagnosed as pulmonary solid adenocarcinoma.


Asunto(s)
Adenocarcinoma del Pulmón , Enfermedades de los Perros , Neoplasias Pulmonares , Perros , Masculino , Animales , Neoplasias Pulmonares/veterinaria , Tos/patología , Tos/veterinaria , Adenocarcinoma del Pulmón/patología , Adenocarcinoma del Pulmón/veterinaria , Pulmón/patología , Tomografía Computarizada por Rayos X , Enfermedades de los Perros/patología
10.
J Vet Med Sci ; 84(7): 898-904, 2022 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-35527017

RESUMEN

A 10-year-old castrated male cat showing behavioral (irritation, prowling, and tumbling) and cutaneous abnormalities such as dermal fragility was diagnosed as hyperadrenocorticism with pituitary macroadenoma, concurrent with insulin dependent diabetes mellitus. Pituitary enlargement (18.0 mm) was observed during magnetic resonance imaging. High endogenous adrenocorticotropic hormone levels (>2,500 pg/ml) were also observed. Although trilostane treatment (5-10 mg/head, daily) was commenced, the clinical signs did not disappear. Insulin and trilostane treatment were discontinued on day 86 after first day of radiation therapy (4 Gy/12 fractions). After radiation therapy, a decreased pituitary tumor size (10.7 mm) was observed on day 301; neurological and dermatological signs exhibited remission. Radiation therapy is the treatment of choice for feline hyperadrenocorticism with pituitary macroadenoma with neurological signs.


Asunto(s)
Hiperfunción de las Glándulas Suprarrenales , Enfermedades de los Gatos , Enfermedades de los Perros , Neoplasias Hipofisarias , Hiperfunción de las Glándulas Suprarrenales/radioterapia , Hiperfunción de las Glándulas Suprarrenales/veterinaria , Animales , Enfermedades de los Gatos/tratamiento farmacológico , Gatos , Dihidrotestosterona/uso terapéutico , Enfermedades de los Perros/patología , Perros , Hidrocortisona , Imagen por Resonancia Magnética/veterinaria , Masculino , Hipófisis , Neoplasias Hipofisarias/diagnóstico , Neoplasias Hipofisarias/radioterapia , Neoplasias Hipofisarias/veterinaria
11.
J Artif Organs ; 14(2): 133-9, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21491113

RESUMEN

Artificial pancreas technology, involving "closed-loop" controls with real-time blood glucose monitoring, has been increasing in reliability as its potential for clinical use and application grows. One such device, based on this technology, is the STG-22 (Nikkiso Co., Ltd., Tokyo, Japan) artificial pancreas apparatus. In order to assess the reliability and accuracy of the device for measuring blood glucose, it is important to compare its readings to those obtained using a 'gold standard' method, such as the hexokinase method. Therefore, in the present study, canine blood [glucose] measurements using the STG-22 were compared to those obtained using a previously established commercial reagent, Quickauto-Neo GLU-HK. Furthermore, two different sample types (whole blood versus plasma constituent) were compared to determine which sample type results in more accurate and optimal readings with the STG-22. Given that the STG-22 was not primarily designed for canine blood samples, results for canine blood samples were not accurate. Measurements performed by the STG-22 with whole blood were significantly lower than reference [glucose] counterparts. Alternatively, an opposite trend was observed with plasma measurements that were significantly higher. A conversion format using the following formula, Hexokinase [glucose] = STG-22 [glucose] × 1.407 + 1.532, was observed with canine samples in our study.


Asunto(s)
Glucemia/análisis , Monitoreo Ambulatorio/veterinaria , Páncreas Artificial/veterinaria , Adulto , Animales , Perros , Femenino , Humanos , Masculino , Monitoreo Ambulatorio/métodos
12.
J Vet Med Sci ; 83(2): 260-266, 2021 Mar 05.
Artículo en Inglés | MEDLINE | ID: mdl-33281143

RESUMEN

Changes in lipoprotein profiles occur in dairy cows during the periparturient period and in cows with transition cow disease. Here, the lipoprotein profiles of Holstein-Friesian dairy cows during the periparturient period were obtained by anion-exchange, high-performance liquid chromatography to evaluate the usefulness of lipoprotein profile evaluation during the periparturient period and in cows with fatty liver and milk fever. Lipoprotein levels (including total and high- (HDL-C) and low-density lipoprotein (LDL-C) cholesterol) in 10 healthy cows were low 4 weeks prepartum, with the lowest values at calving or within 1 week of calving; the values increased at 8 weeks postpartum. The lipoprotein levels were measured in 16 cows diagnosed with fatty liver (n=10) or milk fever (n=6) and compared to 10 healthy dairy cows. A significant difference was observed in HDL-C between healthy cows (at calving and 1 week postpartum), and the fatty liver and milk fever cows. Cows with fatty liver and milk fever had a lower mean HDL-C than the 10 healthy dairy cows at calving and 1 week postpartum. HDL-C might be a good indicator of energy balance for differentiating healthy cows from those with transition cow disease.


Asunto(s)
Lactancia , Leche , Animales , Aniones , Bovinos , Cromatografía Líquida de Alta Presión/veterinaria , Dieta , Metabolismo Energético , Femenino , Lipoproteínas , Periodo Posparto
13.
J Vet Med Sci ; 2021 Mar 05.
Artículo en Inglés | MEDLINE | ID: mdl-33678733

RESUMEN

A 5-year-old castrated male domestic shorthair cat was diagnosed with diabetic ketoacidosis and severe insulin resistance. Although the conventional treatment for diabetic ketoacidosis was provided, the cat required frequent hospitalization because of severe dehydration and repeated diabetic ketoacidosis. We detected anti-insulin antibodies for human in this cat. Serum insulin-binding IgG levels were markedly elevated compared with those in healthy cats and other diabetic cats. We initiated prednisolone to suppress the effects of anti-insulin antibodies. After initiation of prednisolone, the cat was gradually recovered with increasing activity and appetite. Furthermore, satisfactory glycemic control was achieved with combined subcutaneous injection of insulin detemir and insulin degludec.

14.
J Vet Med Sci ; 83(4): 661-665, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33840723

RESUMEN

A 5-year-old castrated male domestic shorthair cat was diagnosed with diabetic ketoacidosis and severe insulin resistance. Although the conventional treatment for diabetic ketoacidosis was provided, the cat required frequent hospitalization because of severe dehydration and repeated diabetic ketoacidosis. We detected anti-insulin antibodies for human in this cat. Serum insulin-binding IgG levels were markedly elevated compared with those in healthy cats and other diabetic cats. We initiated prednisolone to suppress the effects of anti-insulin antibodies. After initiation of prednisolone, the cat was gradually recovered with increasing activity and appetite. Furthermore, satisfactory glycemic control was achieved with combined subcutaneous injection of insulin detemir and insulin degludec.


Asunto(s)
Formación de Anticuerpos , Enfermedades de los Gatos , Cetoacidosis Diabética , Resistencia a la Insulina , Animales , Enfermedades de los Gatos/tratamiento farmacológico , Gatos , Cetoacidosis Diabética/tratamiento farmacológico , Cetoacidosis Diabética/veterinaria , Inmunoglobulina G/inmunología , Insulina/uso terapéutico , Insulina de Acción Prolongada , Masculino
15.
Nihon Hoshasen Gijutsu Gakkai Zasshi ; 66(7): 764-73, 2010 Jul 20.
Artículo en Japonés | MEDLINE | ID: mdl-20702997

RESUMEN

The radiopharmaceutical strontium chloride ((89)Sr) has been released as a new means of pain relief for painful bone metastasis in cancer patients. Because (89)Sr is a pure beta-emitting nuclide, it was considered difficult to know its distribution in the body from outside. Imaging with a gamma camera using bremsstrahlung radiation has been reported as one method, but there has been little detailed basic examination. We examined the optimal energy window and collimator when imaging with a gamma camera using bremsstrahlung radiation produced from (89)Sr beta rays. The results showed that setting the energy window at 75 keV, which is the peak formed by the characteristic X-ray of lead that is produced by the interaction of bremsstrahlung radiation and lead, is optimal for imaging. Also important are the material of the collimator and the use of an MELP collimator.


Asunto(s)
Radiofármacos/metabolismo , Radioisótopos de Estroncio/metabolismo , Cámaras gamma , Humanos , Masculino , Persona de Mediana Edad , Estroncio/metabolismo , Distribución Tisular
16.
J Vet Med Sci ; 82(6): 695-698, 2020 Jun 16.
Artículo en Inglés | MEDLINE | ID: mdl-32307342

RESUMEN

Insulin degludec (IDeg) is a long-acting basal insulin recently developed for use in humans. This study aimed to investigate the effects of IDeg on glycemic control in diabetic cats. Changes in body weight, IDeg dosage, and glycated albumin (GA) were evaluated at 0, 1, 3, 6, 9, and 12 months following initiation of IDeg. A significant decrease in GA was observed and a mean GA level below 25% was achieved between 3 and 12 months. Furthermore, a significant increase in body weight was observed between 3 and 12 months. The mean IDeg dose was 0.75 ± 0.68 IU/kg/day at 12 months. Taken together, long-term glycemic control was successfully achieved in diabetic cats using IDeg.


Asunto(s)
Enfermedades de los Gatos/tratamiento farmacológico , Diabetes Mellitus Tipo 2/veterinaria , Control Glucémico/veterinaria , Hipoglucemiantes/uso terapéutico , Insulina de Acción Prolongada/uso terapéutico , Animales , Gatos , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Femenino , Productos Finales de Glicación Avanzada , Masculino , Albúmina Sérica/metabolismo , Albúmina Sérica Glicada
17.
J Vet Med Sci ; 81(1): 71-76, 2019 Jan 08.
Artículo en Inglés | MEDLINE | ID: mdl-30449819

RESUMEN

A 12-year-old, castrated male cat with diabetes mellitus was diagnosed with acromegaly and examined with magnetic resonance imaging (enlarged pituitary gland, 8 mm); serum hormone concentrations were measured. After the first course of radiation therapy (4 Gy, 12 fractions), insulin administration was not required from day 420 after diagnosis. Enlarged pituitary tumor (8 mm) recurred, and insulin dosage amount of the cat was increased on day 1,065. The second course of radiation therapy (6 Gy, 4 fractions) was performed on day 1,201 and insulin administration was again discontinued. However, the cat died from lymphoma on day 1,397. Postmortem examination revealed pituitary adenoma. Most tumor cells were positive for chromogranin A, synaptophysin, and growth hormone immunohistochemistry. The pancreatic islet cells revealed diffuse hyperplasia. We achieved long-term successful management of an acromegalic cat with two courses of RT. However, a protocol for a second course of RT for feline recurrent pituitary tumor should be further discussed.


Asunto(s)
Acromegalia/veterinaria , Adenoma/veterinaria , Enfermedades de los Gatos/radioterapia , Complicaciones de la Diabetes/veterinaria , Diabetes Mellitus , Neoplasias Hipofisarias/veterinaria , Acromegalia/complicaciones , Acromegalia/diagnóstico , Acromegalia/radioterapia , Adenoma/complicaciones , Adenoma/diagnóstico , Adenoma/radioterapia , Animales , Enfermedades de los Gatos/diagnóstico , Gatos , Complicaciones de la Diabetes/diagnóstico , Complicaciones de la Diabetes/radioterapia , Imagen por Resonancia Magnética/veterinaria , Masculino , Neoplasias Hipofisarias/complicaciones , Neoplasias Hipofisarias/diagnóstico , Neoplasias Hipofisarias/radioterapia , Resultado del Tratamiento
18.
J Vet Med Sci ; 81(12): 1783-1790, 2019 Dec 26.
Artículo en Inglés | MEDLINE | ID: mdl-31611485

RESUMEN

The effects of prescription diets on canine intestinal microbiota are unknown. In this study, we used next generation sequencing to investigate the impact of four commercially available prescription diet regimens on the fecal microbiome in six healthy dogs. The diet regimens used were as follows: weight-loss diet, low-fat diet, renal diet, and anallergenic diet. We found a significantly decreased proportion of phylum Actinobacteria with the weight-loss diet compared to the anallergenic diet. There were no significant differences in the proportion of phylum Bacteroidetes between the four diets. The proportion of phylum Firmicutes was significantly decreased with the weight-loss diet compared to the anallergenic diet. The proportion of phylum Fusobacteria was significantly increased with the weight-loss diet compared to the anallergenic diet. There were no significant differences in the proportion of phylum Proteobacteria after consumption of the four diets. We therefore demonstrated that commercial prescription diet influences the fecal microbiome in healthy dogs. These results might be useful when choosing a prescription diet for targeting a disease.


Asunto(s)
Alimentación Animal , Bacterias/clasificación , Heces/microbiología , Microbioma Gastrointestinal , Animales , Bacterias/genética , Bacterias/aislamiento & purificación , ADN Bacteriano , Dieta/veterinaria , Perros , Femenino , Masculino , Reacción en Cadena de la Polimerasa
19.
Surgery ; 165(1): 25-30, 2019 01.
Artículo en Inglés | MEDLINE | ID: mdl-30413323

RESUMEN

BACKGROUND: We report on the growth of papillary microcarcinoma during active surveillance and before clinical presentation. METHODS: We conducted a retrospective study of 169 patients with papillary microcarcinoma who were enrolled in active surveillance at our hospital between 2000 and 2004. Patients were followed for a median of 10.1 years using serial ultrasonography (median, 12 examinations), used to calculate the tumor doubling time. To contextualize tumor growth rates during active surveillance, we calculated the hypothetical tumor doubling time before clinical presentation. To resolve the limitations in tumor doubling time, tumor doubling rates were inversely transformed into doubling rates. RESULTS: The doubling rates (per year) during active surveillance (median: 0.0) were >0.5, 0.1 to 0.5, -0.1 to 0.1, and <-0.1 in 5, 38, 97, and 29 cases, respectively. The proportions of tumors with rather rapid growth, slow growth, stable, and a decrease in size were 3%, 22%, 57%, and 17%, respectively. CONCLUSION: Tumor growth of papillary microcarcinomas varies from rather rapid growth to a decrease in size during active surveillance.


Asunto(s)
Carcinoma Papilar/diagnóstico por imagen , Carcinoma Papilar/patología , Neoplasias de la Tiroides/diagnóstico por imagen , Neoplasias de la Tiroides/patología , Carga Tumoral , Espera Vigilante , Adulto , Anciano , Progresión de la Enfermedad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Ultrasonografía , Adulto Joven
20.
Thyroid ; 28(1): 23-31, 2018 01.
Artículo en Inglés | MEDLINE | ID: mdl-28629253

RESUMEN

BACKGROUND: Rapid increases in the incidence of thyroid carcinoma with stable mortality rates from thyroid carcinoma have been reported from many countries, and these increases are thought to be due mostly to the increased detection of small papillary thyroid carcinomas (PTCs), including papillary microcarcinomas (PMCs; i.e., PTCs ≤10 mm). Some researchers have suggested that small PTCs have been overdiagnosed and overtreated. In Japan, the active surveillance of patients with low-risk PMCs was initiated by Kuma Hospital (1993) and Tokyo's Cancer Institute Hospital (1995) based on the extremely higher incidences of both latent thyroid carcinomas in autopsy studies and small PTCs detected in mass screening studies using ultrasound examinations compared to the prevalence of clinical thyroid carcinomas. METHODS: The above two institutions' data are summarized regarding the active surveillance of low-risk PMCs, and future prospects for their management are discussed. RESULTS: At 10-year observations in the Kuma Hospital series of 1235 patients, only 8% and 3.8% of the PMC patients showed size enlargement by ≥3 mm and the novel appearance of node metastasis, respectively. In contrast to clinical PTC, PMCs are most unlikely to grow in older patients (≥60 years). In the Kuma Hospital series, the 974 patients who underwent immediate surgery had significantly higher incidences of unfavorable events than the 1179 patients who chose active surveillance. The total cost of immediate surgery, including the costs for salvage surgery and postoperative care for 10 years, was 4.1 times the total cost of 10-year management by active surveillance. Only 8% of the 51 PMC patients showed tumor enlargement during pregnancy, and the rescue surgeries after delivery were successful. In the Cancer Institute Hospital series of 230 patients with 300 lesions, only 7% and 1% of the patients showed size enlargement and novel node metastasis, respectively, and that institution's analysis also revealed that macroscopic or rim calcification and poor vascularity were correlated with non-progressing disease. In both series, none of the patients who underwent rescue surgery after progression signs were detected showed significant recurrence or died of PTC. CONCLUSION: Active surveillance of low-risk PMC can be the first-line management. Interestingly, older patients with low-risk PMCs are the best candidates for active surveillance.


Asunto(s)
Carcinoma Papilar/cirugía , Glándula Tiroides/cirugía , Neoplasias de la Tiroides/cirugía , Tiroidectomía , Progresión de la Enfermedad , Humanos , Japón , Recurrencia Local de Neoplasia/cirugía , Medición de Riesgo , Espera Vigilante
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA